川崎病急性期治疗研究进展

• 作 者: 杨艺
• 出 处: 国际儿科学杂志
• 发表日期: 2021年7期
• 关键词: 川崎病 急性期 治疗

川崎病是一种病因尚不明确的急性全身性血管炎性疾病，约15%～25%未经治疗的患儿发生冠状动脉损害，因此受到越来越多的关注和重视。尽管大剂量静脉注射免疫球蛋白联合口服阿司匹林是目前公认最有效的治疗，但仍有部分患者出现免疫球蛋白无反应及冠状动脉损害，近年来，新的治疗策略包括糖皮质激素、肿瘤坏死因子-α拮抗剂、白细胞介素-1拮抗剂、环孢素A、细胞毒性药物及血浆置换等，其中部分得到了临床肯定，而另一部分尚存在争议。该文就近年来国内外报道的川崎病急性期治疗进展进行综述。“,”Kawasaki disease is an acute systemic vasculitis and its etiology is still unknown.About 15%~25% of untreated children suffer from coronary artery damage, so it has attracted more and more attention around the world.Although high-dose intravenous immunoglobulin and oral aspirin are currently recognized as the most effective treatment.Immunoglobulin resistance and coronary artery damage are still big challenge for some patients.In recent years, new treatments(such as glucocorticoids, TNF-α antagonists, interleukin-1 antagonists, cyclosporin A, cytotoxic drugs, plasma exchange, et al)have been clinically affirmed, and some of them are still controversial.This article reviews the treatment progress of Kawasaki disease in the acute phase at home and abroad in recent years.